Replies to post #115777 on Biotech Values

[ghmm]

NKTR:

Thanks for the quick notes and thanks mcbio for the financing info as well.

Generally speaking I prefer companies to partner (well really I want to keep burn down). That is an often lot of cash they have and the financing was pretty substantial too especially if the convert isn't due soon. I have to relisten/read some calls.

[ghmm]

NKTR:

The PR for AZN starting Phase 3 for 118 came out today.

http://finance.yahoo.com/news/AstraZeneca-Initiates-Phase-prnews-1809736583.html?x=0&.v=1

I've been going over past calls/presentations and still am not sure on the expansion of 102 in ovarian cancer. I know the company line is it gives them a shot (granted low probability) of filing on an open label Phase 2 (in Ovarian Cancer). At first I thought Howard Robin was using it to get better data to partner (even though he claims its not going to be partnered at this stage) but after hearing more calls and his tone I think that (at least for now) that isn't the intent. Then I thought perhaps there is really more data that they need before starting Phase 3 but I am not so sure this is the case either.

I am now a NKTR long :-). My reasons for buying where on total valuation NOT on 102 (I actually think its cheap just on their partnered products alone). Was actually thinking I could add a lot cheaper today.